Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian King from Arzhan (Siberia, Russia)

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2591-2595

  Schultz, Michael ^a   Parzinger, Hermann ^b   Posdnjakov, Dmitrij V ^c   Chikisheva, Tatjana A ^c   Schmidt Schultz, Tyede H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GERMAN ARCHAEOLOGICAL INSTITUTE   (Germany)

^c INSTITUTE OF ARCHAEOLOGY   (Russian Federation)

Author keywords

Extracellular bone matrix proteins; History of tumorous diseases; Paleopathology; Prostate carcinoma; Proteomics

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW; CANCER DIAGNOSIS; ELECTROPHORESIS; HISTOLOGY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEOMICS; RUSSIAN FEDERATION; SCANNING ELECTRON MICROSCOPY; SKELETON; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; BONE NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXTRACELLULAR MATRIX PROTEINS; HISTORY, ANCIENT; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PALEOPATHOLOGY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOMICS; SIBERIA; TUMOR MARKERS, BIOLOGICAL;

EID: 36249006516     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23073     Document Type: Article

References (28)

1. Schmidt-Schultz TH, Schultz M. Bone protects proteins over thousand of years: extraction, analysis, interpretation of extracellular matrix proteins in archaeological skeletal remains. Am J Phys Anthropol 2004;123:30-9.
2. Schmidt-Schultz TH, Schultz M. Intact growth factors are conserved in the extracellular matrix of ancient human bone and teeth: a store-house for the study of human evolution in health and disease. Biol Chem 2005;386:767-76.
3. Schmidt-Schultz TH, Schultz M. Well preserved non-collagenous extracellular matrix proteins in ancient bone and teeth. Int J Osteoarchaeol 2007;17:91-9.
4. Čugunov KV, Parzinger MH, Nagler A. Der skythische Fürstengrabhügel von Aržan 2 in Tuva. Eurasia Antiqua 2003;9:113-62.
5. Schultz M. Paleohistopathology of bone: a new approach to the study of ancient diseases. Yrbk Phys Anthropol 2001;44:106-47.
6. Termine JD, Belcourt AB, Christner PJ, Conn KM, Nylen MU. Properties of dissociatively extracted fetal tooth matrix proteins. J Biol Chem 1980;255:9760-8.
7. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:1970;680-5.
8. Link AJ. 2-D Proteome analysis protocols. Methods in molecular biology, vol. 112. Totowa, NJ: Humana, 1999. 601 p.
9. Swain M, Ross NWA. Silver stain protocol for yielding high resolution and transparent background in sodium dodecyl sulfate-polyacrylamide gels. Electrophoresis 1995;16:948-51.
10. Christensson A, Laurell C-B, Lilja H. Enzymytic activity of prostate specific antigen and its reaction with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-63.
11. Chiarado A. National Institute roundtable on prostate cancer: future research directions. Cancer Res 1991;51:2498-505.
12. Schultz M. Light microscopic analysis in skeletal paleopathology. In: Ortner DJ, ed. Identification of pathological conditions in human skeletal remains. Amsterdam, Boston: Academic Press, 2003. 73-108.
13. Holubec L Jr, Topolcan O, Pikner R, Pecen L, Vaclavickova J, Wirthova M, Molacek J, Stieber P, Holdenrieder S, Sen LH, Finek J. The significance of CEA, CA 19-9 and CA 72-4 in the detection of colorectal recurrence. Anticancer Res 2000;20:5237-44.
14. Klapdor R, Fenner C. Irinotecan (Campto R): efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res 2000;20:5209-12.
15. Resnick D, Niwayma G. Diagnosis of bone and joint disorders, vols. 1-3. Philadelphia, PA: WB Saunders, 1981. 3277 p.
16. Hammerer P, Graefen M, Henke RP, Haese A, Palisaar J, Huland E, Huland H. Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radial prostatectomy. Anticancer Res 2000;20:5253-5.
17. Oremek GM, Kramer W, Seiffert UB, Jonas D. Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease. Anticancer Res 1997;17:3035-6.
18. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA, and CA-19-9 serum levels in colorectal cancer. Anticancer Res 2000;20:5195-8.
19. Anderson WAD. Pathology, vols. 1-2. St. Louis: The CV Mosby Company, 1971. 1862 p.
20. Autzen P, Robson CN, Bjartell A, Malcom AJ, Johnson MI, Neal DE, Hamdy FC. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-23.
21. Boskey AL. Mineral-matrix interactions in bone and cartilage. Clin Orthop 1979;281:244-74.
22. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63.
23. Huber PR, Schmid HP, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Maurer A. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of prostate. Prostate 1995;27:212-9.
24. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1989;279:1542-7.
25. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1995;159:5-12.
26. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
27. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
28. 1-Antichymotrypsin microheterogeneity in crossed immunoaffinoelectrophoresis with free concavalin A: a useful diagnostic tool in inflammatory syndrome. Clin Chem 1988;34:911-5.